Lisa Delfini, Chief Financial Officer at Trevi Therapeutics, Inc. (TRVI), sold 892 shares at $1.75 ($2K) on 2023-03-13, disclosed to the SEC on 2023-03-15.
Scheduled sale ($2k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TRVI | SELL | 2023-09-13 | $2K | — | Filing → |
| TRVI | SELL | 2023-08-14 | $2K | — | Filing → |
| TRVI | SELL | 2023-07-12 | $2K | — | Filing → |